Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Matthay

Showing results (171-180 of 316) with videos related to

Pageof 32
Sort By:
Journal of the National Cancer Institute|February 23, 2019
Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal NeuroblastomaDerek A Oldridge, Bao Truong, Douglas Russ, et al.
Progress in Clinical and Biological Research|January 1, 1991
Response of neuroblastoma to retinoic acid in vitro and in vivoC P Reynolds, D J Kane, P A Einhorn, et al.
Neoplasia (New York, N.Y.)|October 28, 2008
Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 inductionLouis Chesler, David D Goldenberg, Rodney Collins, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group databaseRochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2000
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group StudyM F Ozkaynak, P M Sondel, M D Krailo, et al.
Medical and Pediatric Oncology|December 7, 2000
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastomaL M Choi, N W Kim, J J Zuo, et al.
Pediatric Blood & Cancer|May 23, 2019
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectKevin Campbell, Derek Shyr, Rochelle Bagatell, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 1991
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyD Papahadjopoulos, T M Allen, A Gabizon, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After <sup>131</sup>I- Metaiodobenzylguanidine Therapy in Patients With NeuroblastomaKevin Campbell, Erin E Karski, Aleksandra Olow, et al.
Pageof 32

Showing results (171-180 of 316) with videos related to

Sort By:
Pageof 32
Journal of the National Cancer Institute|February 23, 2019
Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal NeuroblastomaDerek A Oldridge, Bao Truong, Douglas Russ, et al.
Progress in Clinical and Biological Research|January 1, 1991
Response of neuroblastoma to retinoic acid in vitro and in vivoC P Reynolds, D J Kane, P A Einhorn, et al.
Neoplasia (New York, N.Y.)|October 28, 2008
Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 inductionLouis Chesler, David D Goldenberg, Rodney Collins, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group databaseRochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2000
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group StudyM F Ozkaynak, P M Sondel, M D Krailo, et al.
Medical and Pediatric Oncology|December 7, 2000
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastomaL M Choi, N W Kim, J J Zuo, et al.
Pediatric Blood & Cancer|May 23, 2019
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectKevin Campbell, Derek Shyr, Rochelle Bagatell, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 1991
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyD Papahadjopoulos, T M Allen, A Gabizon, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After <sup>131</sup>I- Metaiodobenzylguanidine Therapy in Patients With NeuroblastomaKevin Campbell, Erin E Karski, Aleksandra Olow, et al.
Pageof 32